Meanwhile, it concluded vadadustat did not have a "favourable ... In the first 28 days after treatment started, GSK's drug was associated with a MACE rate of around 14%, versus 10% for ESAs ...

Then just last month it rejected Akebia's vadadustat on the grounds that the ... kept in refrigerated storage unlike injectables. GSK's drug – which is also under regulatory review in Europe ...

An FDA decision looms for Akebia Therapeutics and its proposed vadadustat treatment for anemia due to chronic kidney disease in adults on dialysis. The FDA, which turned away Akebia's initial ...

A summary of the average weighted annual cost for each drug is shown at the top of the unit cost tab in the resource imapct template. When deciding between vadadustat and ESAs, and after the ...